지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2019.1
- 수록면
- 106 - 116 (11page)
이용수
초록· 키워드
오류제보하기
The prevalence of type 2 diabetes mellitus (T2DM), which is associated with cardiovascular morbidity and mortality, is increasing worldwide. Although there have been advances in diabetes treatments that reduce microvascular complications (nephropathy, neuropathy, retinopathy), many clinical studies have found that conventional oral hypoglycemic agents and glucose control alone failed to reduce cardiovascular disease. Thus, incretin-based therapies including glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT-2Is) represent a new area of research, and may serve as novel therapeutics for treating hyperglycemia and modifying other cardiovascular risk factors. Recently, it has been confirmed that several drugs in these classes, including canagliflozin, empagliflozin, semaglutide, and liraglutide, are safe and possess cardioprotective effects. We review the most recent cardiovascular outcome trials on GLP-1RAs and SGLT-2Is, and discuss their implications for treating patients with T2DM in terms of protective effects against cardiovascular disease.
목차
등록된 정보가 없습니다.
참고문헌 (71)
참고문헌 신청
Guariguata L / 2014 / Global estimates of diabetes prevalence for 2013 and projections for 2035 / Diabetes Res Clin Pract 103:137~149
Rawshani A / 2017 / Mortality and cardiovascular disease in type 1 and type 2 diabetes / N Engl J Med 376:1407~1418
Preis SR / 2009 / Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005 / Circulation 119:1728~1735
Wong HK / 2014 / Utilization of glucose, blood pressure, and lipid lowering medications among people with type II diabetes in the United States, 1999-2010 / Ann Epidemiol 24:516~521
Holman RR / 2008 / 10-Year follow-up of intensive glucose control in type 2 diabetes / N Engl J Med 359:1577~1589
Rawshani A / 2017 / Mortality and cardiovascular disease in type 1 and type 2 diabetes / N Engl J Med 376:1407~1418
Preis SR / 2009 / Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005 / Circulation 119:1728~1735
Wong HK / 2014 / Utilization of glucose, blood pressure, and lipid lowering medications among people with type II diabetes in the United States, 1999-2010 / Ann Epidemiol 24:516~521
Holman RR / 2008 / 10-Year follow-up of intensive glucose control in type 2 diabetes / N Engl J Med 359:1577~1589
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study
Diabetes and Metabolism Journal
2022 .07
-
Real-World Treatment Patterns according to Clinical Practice Guidelines in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Korea: Multicenter, Retrospective, Observational Study
Diabetes and Metabolism Journal
2024 .03
-
Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
Diabetes and Metabolism Journal
2017 .01
-
Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
Diabetes and Metabolism Journal
2024 .09
-
A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
Endocrinology and Metabolism
2019 .01
-
새로운 당뇨병 치료제
대한의사협회지
2017 .01
-
Cardiorenal Protection in Diabetic Kidney Disease
Endocrinology and Metabolism
2021 .01
-
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)
Diabetes and Metabolism Journal
2022 .07
-
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)
Diabetes and Metabolism Journal
2022 .07
-
제2형 당뇨병 환자에서 장기간의 Sodium-glucose Cotransporter 2 억제제 치료가 신장기능에 미치는 효과
대한내과학회지
2020 .08
-
Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis
Diabetes and Metabolism Journal
2024 .03
-
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
Diabetes and Metabolism Journal
2023 .05
-
Off-target Effects of Sodium-glucose Cotransporter 2 (SGLT-2) Inhibitor in Cardiovascular Disease
Korean Circulation Journal
2020 .01
-
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
Annals of Pediatirc Endocrinology & Metabolism
2017 .01
-
Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
Endocrinology and Metabolism
2021 .01
-
Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment
Korean Circulation Journal
2021 .01
-
Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: a Korean Diabetes Association and Korean Society of Nephrology consensus statement
Kidney Research and Clinical Practice
2020 .01
-
Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations
Diabetes and Metabolism Journal
2020 .01
-
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea
Diabetes and Metabolism Journal
2015 .01
-
SGLT2 Inhibitors and GLP-1 Agonists: A Beacon of Hope for Stroke Prevention in Diabetes
Diabetes and Metabolism Journal
2024 .03
이 논문의 저자 정보
최근 본 자료
댓글(0)
0